Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    654 result(s) found for: Breast biopsy. Displaying page 8 of 33.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2008-006252-21 Sponsor Protocol Number: 3160A6-2207-WW Start Date*: 2009-05-28
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metast...
    Medical condition: Locally advanced or metastatic ER+/PgR+/erbB2-breast cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015122-11 Sponsor Protocol Number: GBG54 Start Date*: 2012-08-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in m...
    Medical condition: Breast Cancer in Male Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022842-26 Sponsor Protocol Number: UMCNONCO201004 Start Date*: 2010-11-25
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study
    Medical condition: proven invasive adenocarcinoma of the breast
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004513-27 Sponsor Protocol Number: MedOPP127 Start Date*: 2017-09-04
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes
    Medical condition: Hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016743-18 Sponsor Protocol Number: ICG10 Start Date*: 2010-02-02
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Medical condition: Primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002323-38 Sponsor Protocol Number: GBG105GeparPiPPa Start Date*: 2022-08-29
    Sponsor Name:German Breast Group
    Full Title: A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-pos...
    Medical condition: Patients with early breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000394-23 Sponsor Protocol Number: SOLTI-1007 Start Date*: 2012-08-06
    Sponsor Name:SOLTI
    Full Title: A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer
    Medical condition: Patients at Stage I-II HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001155-13 Sponsor Protocol Number: GBG-99-GeparTREIZE Start Date*: 2019-04-02
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer
    Medical condition: Early-staged triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000419-17 Sponsor Protocol Number: AFT-38 Start Date*: 2017-08-25
    Sponsor Name:Alliance Foundation Trials, LLC
    Full Title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatm...
    Medical condition: HER2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000380-13 Sponsor Protocol Number: CP-MGAH22-04 Start Date*: 2015-09-02
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The...
    Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000134-19 Sponsor Protocol Number: AEZS-108-049 Start Date*: 2012-09-07
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: A randomised, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
    Medical condition: Histologically confirmed malignancy of breast tissue; estrogen- and progesterone receptor negative, non overexpressing HER2-receptors, LHRH receptor positive tumor status; receptor status determine...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005834-19 Sponsor Protocol Number: GBG44 Start Date*: 2007-10-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer
    Medical condition: breast cancer, primary systemic therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002971-32 Sponsor Protocol Number: PROICM2019-11PRA Start Date*: 2020-07-27
    Sponsor Name:Institut Regional du Cancer de Montpellier
    Full Title: A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer
    Medical condition: Radio-induced fibrosis in breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006494-24 Sponsor Protocol Number: PACS 08/0610 Start Date*: 2007-06-06
    Sponsor Name:Fédérationa Nationale des Centres de Lutte Contre le Cancer
    Full Title: Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breas...
    Medical condition: non-metastatic operable breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002626-59 Sponsor Protocol Number: 26-02/BIG 4-02 Start Date*: 2005-11-21
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
    Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment program
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057654 LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001727-65 Sponsor Protocol Number: IMCL CP12-0606/TRIO-012 Start Date*: 2009-01-28
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Estudio en fase III, multicéntrico, multinacional, aleatorizado, doble ciego de IMC 1121B más docetaxel frente a placebo más docetaxel en pacientes con cáncer de mama HER2 negativo, irresecable, lo...
    Medical condition: Adenocarcinoma de mama HER2 negativo, metastático o localmente recurrente e irresecable. HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) CZ (Completed) SK (Completed) PL (Completed) GB (Completed) GR (Prematurely Ended) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002818-41 Sponsor Protocol Number: MO42319 Start Date*: 2021-01-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLEBLIND, PLACEBO-CONTROLLED PHASE III STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR PLACEBO IN PATIENTS WITH HER2-POSI...
    Medical condition: Locally advanced / metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) DE (Completed) PT (Completed) NO (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002289-35 Sponsor Protocol Number: SGNLVA-002 Start Date*: 2018-04-02
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast C...
    Medical condition: Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003435-13 Sponsor Protocol Number: MARLENE Start Date*: 2021-05-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer
    Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007310 Carcinoma breast stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 00:24:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA